Partnership combines Apexon's agentic AI platforms and cloud modernization tools with AWS infrastructure to accelerate AI deployment, clinical innovation, and digital transformation across healthcare and life sciences
New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
Clearing 19 biologics for Europe market
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
The company hosted Symbiosis 2026 at its 2-acre manufacturing facility in Bengaluru, inaugurated in 2024
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
Partnership strengthens healthcare technology distribution capabilities, enabling wider reach of Make-in-India medical devices through government and institutional healthcare networks
CDMO strengthens global quality framework through digital transformation, AI-enabled investigations, workforce development and continuous audit readiness
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
Subscribe To Our Newsletter & Stay Updated
